MX2020004542A - Metodo para inactivar el virus del zika y para determinar la inactivacion total. - Google Patents

Metodo para inactivar el virus del zika y para determinar la inactivacion total.

Info

Publication number
MX2020004542A
MX2020004542A MX2020004542A MX2020004542A MX2020004542A MX 2020004542 A MX2020004542 A MX 2020004542A MX 2020004542 A MX2020004542 A MX 2020004542A MX 2020004542 A MX2020004542 A MX 2020004542A MX 2020004542 A MX2020004542 A MX 2020004542A
Authority
MX
Mexico
Prior art keywords
inactivation
determining
completeness
zika virus
inactivating
Prior art date
Application number
MX2020004542A
Other languages
English (en)
Inventor
Jill A Livengood
Holli Giebler
Hansi Dean
Tatsuki Satou
Raman Rao
Jackie Marks
Mark Lyons
Asae Shintani
Jamie Gifford
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2020004542A publication Critical patent/MX2020004542A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Métodos para inactivar un virus del Zika que pueden ser usados en vacunas y composiciones inmunogénicas. Además, un método para determinar que se haya completado la inactivación de una preparación de arbovirus.
MX2020004542A 2017-11-03 2018-11-05 Metodo para inactivar el virus del zika y para determinar la inactivacion total. MX2020004542A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581500P 2017-11-03 2017-11-03
US201762592995P 2017-11-30 2017-11-30
PCT/US2018/059227 WO2019090233A2 (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation

Publications (1)

Publication Number Publication Date
MX2020004542A true MX2020004542A (es) 2020-09-18

Family

ID=64427224

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020004543A MX2020004543A (es) 2017-11-03 2018-11-05 Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
MX2020004542A MX2020004542A (es) 2017-11-03 2018-11-05 Metodo para inactivar el virus del zika y para determinar la inactivacion total.
MX2020004367A MX2020004367A (es) 2017-11-03 2018-11-05 Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020004543A MX2020004543A (es) 2017-11-03 2018-11-05 Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020004367A MX2020004367A (es) 2017-11-03 2018-11-05 Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.

Country Status (12)

Country Link
US (5) US11730802B2 (es)
EP (3) EP3703739A2 (es)
JP (4) JP2021502350A (es)
KR (3) KR20200083571A (es)
CN (3) CN111615397A (es)
AU (6) AU2018359660B2 (es)
BR (3) BR112020008693A2 (es)
CA (3) CA3081581A1 (es)
MX (3) MX2020004543A (es)
MY (2) MY194449A (es)
SG (3) SG11202003949TA (es)
WO (3) WO2019090238A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194449A (en) 2017-11-03 2022-11-30 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
MX2020004633A (es) * 2017-11-30 2020-09-28 Takeda Vaccines Inc Metodo para inactivar el virus de zika y metodos relacionados.
BR112021019845A2 (pt) * 2019-05-08 2022-02-15 Takeda Vaccines Inc Composições de vírus inativado e formulações de vacina contra zika
EP4153222A1 (en) 2020-05-20 2023-03-29 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2022076865A1 (en) 2020-10-09 2022-04-14 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
CN112980805B (zh) * 2021-02-25 2022-11-08 中国科学院广州生物医药与健康研究院 一种重组寨卡病毒减毒株及其制备方法和应用
CN112941201B (zh) * 2021-03-01 2022-03-08 武汉珈创生物技术股份有限公司 一种用于多细胞种属鉴别和交叉污染检测的混合引物及其使用方法
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR102619184B1 (ko) * 2022-12-27 2023-12-29 주식회사 그린백스 에피갈로카테킨-3-갈레이트에 의해 불활화된 지카바이러스를 유효성분으로 포함하는 백신 조성물

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
DE69015222T2 (de) 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
CA2253549C (en) 1996-06-18 2005-10-25 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
JP4153999B2 (ja) 1996-12-20 2008-09-24 アルザ・コーポレーション 経皮作用剤流量を強化するための組成物と方法
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6309650B1 (en) 1997-08-28 2001-10-30 Cheil Jedang Corporation Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
JP2001519162A (ja) 1997-10-07 2001-10-23 ユニバーシティ・オブ・メリーランド・バイオテクノロジー・インスティチュート 動物細胞にｒｎａを導入して発現させる方法
AU756828B2 (en) 1997-12-02 2003-01-23 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
ES2286905T3 (es) 1998-12-02 2007-12-01 University Of Maryland, Baltimore Sistema de estabilizacion de plasmidos para el suministro de antigenos.
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
AU2001297770B2 (en) 2000-11-22 2007-04-05 University Of Maryland, Baltimore Use of CLyA hemolysin for excretion of fusion proteins
GB0326439D0 (en) 2003-11-13 2003-12-17 Imp College Innovations Ltd Methods
BRPI0419023A (pt) 2004-08-27 2007-12-11 Panacea Biotec Ltd vacina contra poliomielite inativada e derivada do genero sabin de vìrus da polio
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
EP1724338A1 (en) 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
CN101516395B (zh) 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
CA2756206A1 (en) 2009-03-27 2010-09-30 Academia Sinica Methods and compositions for immunization against virus
US20100310656A1 (en) 2009-04-27 2010-12-09 Immunitor USA, Inc. Immunotherapy and prevention of autoimmune hepatitis
SG194950A1 (en) 2011-05-26 2013-12-30 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine
US9844588B2 (en) 2011-06-17 2017-12-19 Bharat Biotech International Limited Inactivated chikungunya viruses (CHIKV) comprising an E1-K211E mutation
DK3106176T3 (en) 2011-12-06 2018-01-08 Valneva Austria Gmbh ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2015059714A1 (en) 2013-09-14 2015-04-30 Bharat Biotech International Limited Emergency mode in a hybrid vehicle
SG11201702116VA (en) 2014-09-17 2017-04-27 Univ Iowa Res Found Viral rna segments as immunomodulatory agents and vaccine components
US10485862B2 (en) 2014-10-07 2019-11-26 Serum Institute Of India Pvt Ltd Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
WO2016209805A1 (en) 2015-06-22 2016-12-29 President And Fellows Of Harvard College Compositions and methods for modulating viral infection
EA035921B1 (ru) * 2015-07-16 2020-08-31 Бхарат Байотек Интернэшнл Лимитед Вакцинные композиции для профилактики арбовирусных инфекций
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
WO2017056094A1 (en) 2015-09-30 2017-04-06 Ramot At Tel-Aviv University Ltd. Attenuated virus mutated at sites of evolutionarily conserved rna structure
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
DK3393510T3 (da) 2015-12-23 2023-03-13 Valneva Austria Gmbh Zikavirusvaccine
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
US11434259B2 (en) 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
JP7012365B2 (ja) 2016-02-25 2022-03-04 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ジカウイルスに対する新規のワクチン
US20170354729A1 (en) 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2017192856A1 (en) 2016-05-04 2017-11-09 University Of Miami Zika virus vector for treating zika virus infection
ES2929274T3 (es) 2016-05-10 2022-11-28 Najit Tech Inc Inactivación de patógenos y producción de vacunas inactivadas altamente inmunógenas utilizando un proceso de oxidación dual
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
US10967057B2 (en) 2016-06-02 2021-04-06 Glaxosmithkline Biologicals S.A. Zika viral antigen constructs
US10611801B2 (en) 2016-06-09 2020-04-07 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing and treating Zika virus infection
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
US10947277B2 (en) 2016-06-13 2021-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
WO2018009603A1 (en) 2016-07-08 2018-01-11 The United State of America, as represented by the Secretary, Department of Health and Human Service Chimeric west nile/zika viruses and methods of use
WO2018007575A1 (en) 2016-07-08 2018-01-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Genomic sequences encoding for an attenuated mutant zika virus
US11834494B2 (en) 2016-07-26 2023-12-05 Washington University Antibodies to zika virus and methods of use thereof
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
WO2018091540A1 (en) 2016-11-17 2018-05-24 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
US20190358313A1 (en) 2016-12-23 2019-11-28 Expres2Ion Biotechnologies Aps New flavivirus vaccine
CN108503697B (zh) 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 一种果蝇细胞表达的寨卡病毒亚单位疫苗
CN108503696B (zh) 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 一种酵母细胞表达的寨卡病毒亚单位疫苗
WO2018165373A1 (en) 2017-03-08 2018-09-13 University Of Georgia Research Foundation, Inc. Methods and compositions related to increased viral production
WO2018187799A1 (en) 2017-04-07 2018-10-11 The Rockefeller University Compositions and methods related to human neutralizing antibodies to zika and dengue 1 virus
US11286502B2 (en) 2017-06-20 2022-03-29 Texas Tech University System ZIKA virus like particle (VLP) based vaccine and microneutralization assay
EP3417943B1 (de) 2017-06-21 2020-02-12 Eppendorf AG Zentrifugenrotor mit abdichtung
CN107188935B (zh) * 2017-07-20 2018-10-02 北京健乃喜生物技术有限公司 一种寨卡病毒ns1抗原突变体及其应用
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN107537029B (zh) 2017-09-14 2021-03-19 北京科兴生物制品有限公司 一种寨卡病毒与黄热病毒联合灭活疫苗
GB201716254D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
MY194449A (en) 2017-11-03 2022-11-30 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
BR102017024030A2 (pt) 2017-11-08 2019-06-04 Universidade Federal De São João Del Rei Proteína recombinante imunogênica com antígenos de zika virus para vacina e seus usos
US20210054055A1 (en) 2017-11-21 2021-02-25 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
MX2020004633A (es) 2017-11-30 2020-09-28 Takeda Vaccines Inc Metodo para inactivar el virus de zika y metodos relacionados.
CN108187036A (zh) 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 一种寨卡病毒与乙脑病毒联合灭活疫苗
CN108210921A (zh) 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 一种寨卡病毒疫苗及其制备方法
EP3755818A1 (en) 2018-02-22 2020-12-30 Nano4 Global, Lda Method for detecting flaviviridae
SG11202008126QA (en) 2018-03-08 2020-09-29 Codagenix Inc Attenuated flaviviruses
WO2019186199A1 (en) 2018-03-29 2019-10-03 Emergex Vaccines Holding Limited Vaccine compositions
KR102075581B1 (ko) 2018-04-27 2020-02-10 가톨릭대학교 산학협력단 바이러스성 발현 조절 서열이 삽입된 핵산 분자를 포함하는 면역보강제 및 이를 포함하는 약학 조성물
KR102253190B1 (ko) 2018-07-18 2021-05-18 (주)진매트릭스 지카 바이러스 변이주와 이를 포함한 지카 백신 조성물
EP3851120A4 (en) 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE, AND APPLICATION THEREOF
EP3870208A4 (en) 2018-10-26 2022-10-26 New York Blood Center, Inc. IMMUNOGENIC COMPOSITIONS OF THE ZIKA VIRUS
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
BR112021019845A2 (pt) 2019-05-08 2022-02-15 Takeda Vaccines Inc Composições de vírus inativado e formulações de vacina contra zika
US20230272405A1 (en) 2020-06-22 2023-08-31 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor

Also Published As

Publication number Publication date
US11964008B2 (en) 2024-04-23
AU2018359660A1 (en) 2020-05-28
JP7295124B2 (ja) 2023-06-20
KR20200083571A (ko) 2020-07-08
CN111615397A (zh) 2020-09-01
AU2022201109B9 (en) 2022-05-12
SG11202003949TA (en) 2020-05-28
AU2022201109A1 (en) 2022-03-10
CN111511395A (zh) 2020-08-07
EP3703740A2 (en) 2020-09-09
WO2019090233A2 (en) 2019-05-09
AU2022209239B2 (en) 2023-10-05
AU2018359558C1 (en) 2022-09-22
US20230145065A1 (en) 2023-05-11
JP2021502350A (ja) 2021-01-28
AU2018359558B2 (en) 2021-12-02
MX2020004543A (es) 2020-09-18
US11648304B2 (en) 2023-05-16
US11478541B2 (en) 2022-10-25
AU2018359558A1 (en) 2020-05-28
AU2022201109B2 (en) 2022-04-28
KR20200085302A (ko) 2020-07-14
US20210177958A1 (en) 2021-06-17
AU2018359556B2 (en) 2021-12-02
JP7443232B2 (ja) 2024-03-05
SG11202003796XA (en) 2020-05-28
AU2022203422A1 (en) 2022-06-09
CA3081578A1 (en) 2019-05-09
WO2019090228A2 (en) 2019-05-09
JP2023175761A (ja) 2023-12-12
CA3081586A1 (en) 2019-05-09
CN111526885A (zh) 2020-08-11
JP2021505648A (ja) 2021-02-18
MY193736A (en) 2022-10-27
WO2019090238A1 (en) 2019-05-09
JP2021502075A (ja) 2021-01-28
AU2018359556A1 (en) 2020-05-28
WO2019090233A3 (en) 2019-06-13
US20200360505A1 (en) 2020-11-19
US20230414743A1 (en) 2023-12-28
AU2018359660B2 (en) 2022-02-24
SG11202003800YA (en) 2020-05-28
EP3703741A1 (en) 2020-09-09
US20210177959A1 (en) 2021-06-17
MX2020004367A (es) 2020-10-19
BR112020008693A2 (pt) 2020-10-13
EP3703739A2 (en) 2020-09-09
KR20200117981A (ko) 2020-10-14
BR112020008652A2 (pt) 2020-11-10
AU2022203422B2 (en) 2023-10-05
US11730802B2 (en) 2023-08-22
BR112020008665A2 (pt) 2020-11-10
WO2019090228A3 (en) 2019-06-20
CA3081581A1 (en) 2019-05-09
MY194449A (en) 2022-11-30
AU2022209239A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
MX2020004542A (es) Metodo para inactivar el virus del zika y para determinar la inactivacion total.
PH12018500127A1 (en) Vaccine compositions
MX2020004633A (es) Metodo para inactivar el virus de zika y metodos relacionados.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
CL2018000609A1 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue.
CU20170044A7 (es) Método mejorado para producir una composición de partículas enterovirales a través de la inactivación del enterovirus y la adsorción en coadyuvantes
BR112016024084A2 (pt) mecanismo de manipulação de temporizador aprimorado
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
AR089995A1 (es) Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
AR104271A1 (es) Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
EP4226936A3 (en) Non-neuroinvasive viruses and uses thereof
MX2017015004A (es) Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
AR113831A1 (es) Métodos para desactivar un virus de zika y para determinar la desactivación total
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX2018011226A (es) Tc24-c4, antígeno de vacuna de la enfermedad de chagas con estabilidad mejorada y agregación disminuida.
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
UA92404U (ru) Способ инактивации инфекционных свойств гемагглютинирующих вирусов
CU24686B1 (es) Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b
CO2020004314A2 (es) Método para invertir la base del contenedor antes del enfriamiento
DOP2016000001A (es) Tecnologia de procesamiento del grano integral del café para la producción de sustancias y productos ecológicamente limpios hacia una agroindustria sostenible
RU2014146753A (ru) Способ воздействия лофанта анисового на гиперхолестеринемию